Get Level 2

If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share Regulatory News
  5. Form-20F Publication

Pin to quick picksHutchmed Regulatory News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
178.00    3.00 (1.71%)
Bid:
176.50
Ask:
178.00
Spread: 1.50 (0.85%)
Market Cap: £1.53b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Form-20F Publication

3 Mar 2020 14:18

RNS Number : 8821E
Hutchison China Meditech Limited
03 March 2020
 

 

 

Press release

 

Publication of Form 20-F

 

 

London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ("Chi-Med") (NasdaqAIM: HCM) today published the Form 20-F for the financial year ended December 31, 2019. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8821E_1-2020-3-3.pdf and also on the website of the Company at www.chi-med.com.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

CONTACTS

Investor Enquiries

 

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com

Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)xyang@troutgroup.com

 

 

Media Enquiries

 

UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)bmiles@troutgroup.com

Asia

- Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)jlo@brunswickgroup.com

 

- Zhou Yi, Brunswick

+852 9783 6894 (Mobile)yzhou@brunswickgroup.com

 

 

Nominated Advisor

 

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAJJMITMTMMBIM
67891011121314
Date   Source Headline
29th Jun 20187:02 amRNSTotal Voting Rights
29th Jun 20187:01 amRNSBlocklisting Six Monthly Return
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights
30th Apr 20187:00 amRNSTotal Voting Rights
27th Apr 20181:52 pmRNSResults of Annual General Meeting
23rd Apr 20181:10 pmRNSGrant of Share Options under Share Option Scheme
23rd Apr 20181:05 pmRNSBlock Admission
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20187:00 amRNSVesting of awards under Long Term Incentive Plan
26th Mar 20187:00 amRNSAnnual Report & Notice of Annual General Meeting
21st Mar 20189:25 amRNSDirector's Share Dealing
20th Mar 20189:15 amRNSGrant of Share Options under Share Option Scheme
19th Mar 20187:10 amRNSDirector's Share Dealing
12th Mar 201811:22 amRNSPublication of Form 20-F
12th Mar 20187:02 amRNSFinal Results and Key Clinical Programs Update
6th Mar 20187:00 amRNSPhase Ib/II Trial of Epitinib in Glioblastoma
13th Feb 20187:01 amRNSEnrolment completed Ph III FALUCA Fruquintinib
5th Feb 20187:00 amRNSChi-Med to Announce 2017 Final Results
29th Dec 20177:00 amRNSBlock listing Interim Review
29th Dec 20177:00 amRNSTotal Voting Rights
15th Dec 20177:00 amRNSChi-Med Initiates Fruquintinib US Clinical Trials
1st Nov 20179:45 amRNSNotification of Major Holdings
1st Nov 20179:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
31st Oct 20177:00 amRNSFRUTIGA, a Phase III trial of Fruquintinib
30th Oct 20173:30 pmRNSClosing of U.S. Public Offering of ADSs
27th Oct 201712:10 pmRNSChi-Med Announces Over-allotment Option
26th Oct 20177:00 amRNSChi-Med Announces Pricing Raising US$262 million
25th Oct 20177:00 amRNSChi-Med Announces Proposed Offering of ADSs
19th Oct 20179:20 amRNSNotification of Major Interest in Shares
17th Oct 20177:00 amRNSSavolitinib Shows Encouraging Clinical Activity
16th Oct 20177:00 amRNSChi-Med Reports Preliminary Phase II data
12th Oct 20177:30 amRNSAppointment of Director
29th Sep 20177:04 amRNSSavolitinib and Fruquintinib presentations at WCLC
29th Sep 20177:00 amRNSOral Presentations at CSCO Annual Meeting
29th Sep 20177:00 amRNSTotal Voting Rights
31st Aug 201710:15 amRNSDirector's Share Dealing
29th Aug 20177:00 amRNSStart of HMPL 689 Phase I Trial in China
22nd Aug 20179:00 amRNSDirector's Share Dealing
18th Aug 201710:50 amRNSDirectors' Share Dealing
15th Aug 201710:30 amRNSDirectors' Share Dealing
10th Aug 20179:35 amRNSDirector's Share Dealing
7th Aug 20179:45 amRNSDirectors' Share Dealing
31st Jul 20177:00 amRNSChi-Med Reports 2017 Interim Results
30th Jun 20177:00 amRNSTotal Voting Rights
29th Jun 20177:00 amRNSChi-Med to Announce 2017 HY Financial Results
29th Jun 20177:00 amRNSBlocklisting Six Monthly Return
29th Jun 20177:00 amRNSStart of Savolitinib Global PRCC Phase III Trial
67891011121314

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
PGR
PGR.L
LSE
0.00%
TIFS
TI Fluid Systems
LSE
0.00%
TFG
Tetragon Fin
LSE
0.00%
POW
Power Metal Resources PLC
LSE
1.04%
OGN
Origin
LSE
0.00%
Trending
HEX
Helix Exploration
LSE
-7.88%
KOD
Kodal Minerals
LSE
3.17%
HEMO
Hemogenyx Pharmaceuticals
LSE
2.67%
LLOY
Lloyds
LSE
0.35%
RRR
Red Rock Resources
LSE
0.00%